Tag: fireside chat

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

EDEN PRAIRIE, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, today announced that President and Chief Executive Officer Michael Happe will participate in an analyst-led fireside chat at the Baird 2026 Global Consumer, Technology & Services Conference in New York City at 10:50 a.m. ET on Wednesday, June 3, 2026. Management will also host one-on-one meetings with institutional investors and analysts.

Palo Alto, California, June 02, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced that Oren Elkayam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies 2026 Defense Technology Virtual Summit.

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

ROCHESTER, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2025 Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 in Boston, MA. The presentation is scheduled to begin at 3:45 p.m. ET and is expected to cover the company’s financial metrics, operating performance, strategic business initiatives, and outlook for the future.

STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.